African trypanosomiasis is associated with Trypanosoma evansi, T. vivax, T. congolense,
and T. brucei pathogens in African animal trypanosomiasis (AAT) while T. b gambiense and …

This review discusses the challenges of chemotherapy for human African trypanosomiasis
(HAT). The few drugs registered for use against the disease are unsatisfactory for a number …

Human African trypanosomiasis (sleeping sickness) occurs in sub-Saharan Africa. It is
caused by the protozoan parasite Trypanosoma brucei, transmitted by tsetse flies. Almost all …

Despite the many decades of use of most of the current trypanocides, we know little of their
mode of action. This may in part be because most of these will act on multiple targets once …

Humanitarian agencies are increasingly engaged in research in conflict and post-conflict
settings. This is justified by the need to improve the quality of assistance provided in these …

Human African trypanosomiasis or 'sleeping sickness 'is a neglected tropical disease
caused by the parasite Trypanosoma brucei. A decade of intense international cooperation …

Despite the fact that eflornithine was considered as the safer drug to treat human African
trypanosomiasis (HAT) and has been freely available since 2001, the difficulties in logistics …

Human African trypanosomiasis (HAT) is responsible for around 3000 reported cases each
year. Treatments for HAT are expensive and problematic to administer, and available drugs …

Treatment of second-stage gambiense human African trypanosomiasis relied on toxic
arsenic-based derivatives for over 50 years. The availability and subsequent use of …

Background. Existing diagnostic and treatment tools for human African trypanosomiasis
(HAT) are limited. The recent development of nifurtimox-eflornithine combination therapy …